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Introduction
The factors that affect the progression of prostatic car-
cinoma are poorly understood, but it is known that car-
bohydrate antigens on the tumour cell surface play 
a role in the transforming and metastatic processes [1].
Although numerous "biochemical tumour markers"
have been investigated as potential markers for detect-
ing the capacity for progression of prostatic carcino-
ma, including lectins and monoclonal antibodies
against many carbohydrate antigens, to date there are
no reports of tumour-associated antigens in prostatic
carcinoma. Without exception, these markers proved
disappointing in that they do not give consistent results
in all cases, and are not specific for, or unique to, pro-
static carcinoma. Most of these studies failed to map
the sequential steps in the synthesis of the type I and II
chain carbohydrate structures, which bind to different
markers of transformed prostatic cells. The changes in
glycosylation that occur in transformed cells can take
a variety of forms. Examples have been found of loss
of expression or excessive expression of certain struc-
tures, the persistence of incomplete or truncated struc-
tures, the accumulation of precursors, and, less com-
monly, the appearance of novel structures [2,3]. Most
of the studies that analysed the glycans phenotype of
prostatic carcinoma also failed to relate the staining
pattern to the chemical structures.
Because the significant morbidity and mortality
associated with prostate cancer can universally be attrib-
uted to the consequences of metastases; the goal of the
present report was to perform a comparative, lectin-his-
tochemical study of noncancerous prostate and carcino-
ma of prostate with at least two metastasises. 
A battery of 19 markers (most of them had not
been used in previous studies) including 15 lectins in
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against Lewis antigens and polyclonal antibody
against prostate specific antigen were used in a semi
quantitative study to investigate the changes in gly-
cosylation patterns occur in prostatic carcinoma.
Materials and methods
Ten formalin-fixed, paraffin-embedded specimens of grossly non-
cancerous human prostate (normal prostate, prostate hypertrophy
and prostatitis) and twenty seven cases of high grade prostatic car-
cinoma (8-10 Gleason score) surgically excised in a 20-year peri-
od prior to radio therapeutic, chemotherapeutic and hormonal
manipulation regimes, are obtained from the histopathology
archive of the Manchester Royal Infirmary.
The mean age of the cases was 72 years (range 50 to 92 years).
Twenty seven of prostatic carcinoma had metastases; deposits were
present in the following sites: lymph nodes (18), bone (14), lung
(16), liver (12), adrenal (8), pituitary (3), pancreas (2), spleen (2),
bladder (3), kidney (2), cerebellum (1), thyroid (2), and breast (1).
Lectin histochemistry. Sections were deparaffinised, the endoge-
nous peroxidase was blocked in methanolic hydrogen peroxide and
they were then hydrated through graded ethanols to water. They
were pre-treated with a solution of 0.1% (w/v) trypsin (type II
crude, from porcine pancreas, Sigma Chemical Co.) in 0.05 M
TRIS buffered saline (TBS), pH 7.6 containing 0.1% (w/v) calci-
um chloride. After washing, they were stained with the panel of 15
biotinylated lectins (Table 1) using a lectin-biotin avidin-peroxi-
dase method [4], with DAB as the disclosing agent and a methyl
green counter stain. Most biotinylated lectins were obtained from
the Sigma Chemical Company, MAA and SNA from Boehringer
Mannheim. All were used at a concentration of 10 μg/ml apart
from MAA and SNA, which were used at 50 μg/ml. 
Negative control sections were included in every staining run
with buffer replacing the lectin and, where possible, controls were
carried out using the appropriate competing sugars. Positive con-
trols were also carried out, variously by using other tissues within
the section or by using known 'positive' slides from blocks of other
tissues.
Digestion with dilute acid was performed by incubating addi-
tional sections in diluted sulphuric acid "0.1M H2SO4" (BDH) for
24 hours at 4°C, prior to staining with 15 lectins. This digestion
was used as a control for the staining by SNA and MAA and also
to determine the sub-terminal sugars. 
Beta-elimination was performed, before staining with 
15 lectins, based on the method of Downs et al [5].
Immunohistochemistry.Apanel of antibodies including polyclon-
al antibody against prostate specific antigen "PSA" (Dako), and
monoclonal antibodies against Lewisa (MAb Lea), sialyl Lewisa
(MAb sLea) (Novocastra Laboratories Ltd.) and sialyl Lewisx
(MAb sLex) (Chemicon International Ltd.) glycans (Table 1) was
applied to the same cases of prostatic carcinoma. Sections (5 χm)
were de-waxed, the endogenous peroxidase was blocked in
methanolic hydrogen peroxide, and they were then hydrated
through graded ethanols to water. They were microwaved for 
5 minutes in low power (106 w) after boiling the sodium citrate
buffer pH 6.0. After washing, non-specific staining was blocked by
incubating the slides in diluted normal goat serum (NGS) for 20
minutes, followed by treatment with primary antibody diluted in
0.5-1% (w/v) BSA (bovine serum albumin) in TBS + 0.01% (w/v)
sodium azide for 60 minutes at room temperature 17-21°C. After
washing in two changes of TBS, slides were treated with secondary
antibody, 1/300 (v/v) biotinylated goat anti-mouse diluted in 0.5-
1% (w/v) BSA in TBS + 0.01% (w/v) sodium azide, and incubated
for 40 minutes at room temperature then rinsed as before in TBS.
The slides were treated with 0.2% v/v streptavidin peroxidase dilut-
ed in TBS for 30 minutes at room temperature. After washing in
TBS, DAB (3,3'diaminobenzidine tetrahydrochloride) was applied
for 5-10 minutes and the slides counter-stained in Mayer's haema-
toxylin.
The tissue components analysed were stroma, prostatic ducts,
epithelium (basement membrane, luminal secretions, cytoplasm,
apex, apical secretion, apical membrane, lateral membrane, supra-
nucleus, nuclear membrane and nucleoplasm). In some cases of
prostatic carcinoma, it was not possible to analyse glandular
epithelial cells in such detail because of cellular pleomorphism and
irregular acinar formation.
Results
The current study showed PSA is present in the cyto-
plasm of benign and malignant prostate epithelium of
all cases.
Lectin specificity and the validity of the lectin his-
tochemistry were confirmed by the different controls.
There was a different staining of noncarcinous prosta-
tic tissue and prostatic carcinomas with lectins and
antibodies, the main findings are summarised and
arranged in groups according to the markers and their
ligand carbohydrate structures in Table 2. The experi-
ments with the inhibitory sugars completely blocked
the lectin binding. 
Normal prostatic tissue
In the normal prostate AAA, UEA-1 and DBA bound
weakly to the membranes of less than 10% of elective
cell population of epithelial cells. Monoclonal anti-
bodies against Lewis antigens showed almost no bind-
ing except MAb Lea that bound to less than 10% of
elective cell population of epithelial cells. WFA
showed no binding, whereas VVA and HPA bound
weakly to a few cells. BSA-1B4 revealed strong stain-
ing pattern in up to 10% of normal epithelium. MPA,
ECA and AHA demonstrated strong binding to selec-
tive epithelial cell and luminal secretions, and were
negative in some cases, while CTA was weakly bound
in some cases. GNAand NPAillustrated a moderate to
strong binding pattern in the epithelium. SNA and
MAA demonstrated a moderate binding to the cyto-
plasm and membranes of the epithelium. 
Malignant prostatic tissue 
AAA, UEA-1, DBA, MAb Lea, MAb sLea and MAb
sLex. The number of prostatic carcinoma cases that
bound to the AAA, UEA-1, DBA, MAb Lea, MAb sLea
and MAb sLex markers varied in regard to site, pro-
portion of positive malignant cells and the pattern of
staining. Approximately 70% of the cases of prostatic
carcinoma bound to AAA, 51% to UEA-1, 37% to
DBA, 78% to MAb Lea, 78% to MAb sLea and 82% 
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Fig. 1. UEA-1 staining profile of prostatic carcinoma (original magnification ×40). Fig. 2. DBA staining profile of prostatic carcinoma
(original magnification ×10). Fig. 3. MAb Lea staining profile of prostatic carcinoma (original magnification ×20). Fig. 4. MAb sLea
staining profile of prostatic carcinoma (original magnification ×10). Fig. 5. MAb sLex staining profile of prostatic carcinoma (original
magnification ×20). Fig. 6.1 WFAstaining profile of prostatic carcinoma (original magnification ×10). Fig. 7. HPAstaining profile of pro-
static carcinoma (original magnification ×20). Fig. 8. VVA staining profile of prostatic carcinoma (original magnification ×20). 
Fig. 9. BSA-1B4 staining profile of prostatic carcinoma (original magnification ×10). Fig. 10. MPA staining profile of prostatic carcino-
ma (original magnification ×10). Fig. 11. AHA staining profile of prostatic carcinoma (original magnification ×20). Fig. 12. ECA stain-
ing profile of prostatic carcinoma (original magnification ×20). Fig. 13. CTA staining profile of prostatic carcinoma (original magnifica-
tion ×40). Fig. 14.3 SNA staining profile of prostatic carcinoma (original magnification ×20). Fig. 15. MAA staining profile of prostatic
carcinoma (original magnification ×20).640 M.N. Khabaz et al.
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to MAb sLex. In most cases, less than 5% of the
tumour cells (glandular and ductal epithelium) bound
to the above lectins, but in a few cases up to 70% of
tumour cells bound to AAA and UEA-1. Almost one
third of the prostatic carcinomas expressed Lewis anti-
gens in up to 80% of the tumour cells. The markers
above showed a granular pattern of staining, mostly
apical and membranous, within certain cell popula-
tions of the malignant prostatic epithelium of the
tumours (Figs 1, 2, 3, 4 and 5). They also showed
patches of staining within the stroma. 
WFA, VVA and HPA. WFA bound strongly to
luminal secretions and the apices of epithelial cells
within the malignant prostatic epithelium (glandular
and ductal) and also bound moderately to stroma in a
patchy manner. This staining profile was present in all
tumours (Fig. 7), irrespective of grade of prostatic car-
cinoma. Some areas of poorly differentiated carcinoma
showed a diffuse cytoplasmic pattern of staining. The
intensity of stain was inconsistent in some parts of the
tumours in some cases (focal). HPA and VVA gave
variable results, showing binding by 24 and 21 prosta-
tic carcinomas respectively. The HPA staining pattern
resembled the WFAstaining profile in most of the pro-
static carcinomas, but with a wide degree of variation
in regard to intensity and proportion of positive cells
(Fig. 8). In contrast, VVA gave a patchy pattern of
staining with a strong tendency to bind to subsets of
cells (Fig. 9). It bound to less than 40% of the malig-
nant epithelium in the prostatic carcinomas. 
BSA-1B4. SA-1B4 gave unexpected results. It was
expected to be negative, but appeared to be positive in
19 of the prostatic carcinomas (Fig. 10). The staining
pattern, which was mostly selective and granular, was
concentrated in the apex, the membranes and the puta-
tive location of the Golgi apparatus. 
MPA, ECA, CTA and AHA. MPA bound strongly
in a uniform pattern to the vast majority of malignant
prostatic epithelia in 26 out of 27 prostatic carcinomas.
It showed a strong granular cytoplasmic stain especial-
ly in the apex, apical secretions and membranes in pro-
static carcinomas (Fig. 11). In comparison, AHA
Table 1. Specificities of lectins (agglutinins) and monoclonal antibodies.
Fuc: fucose; Gal: galactose; GlcNAc: 2 deoxy, 2 acetamidoglucosyl residue; GalNAc: 2 deoxy, 2 acetamidogalactosyl residue; Man: mannose; NeuAc:
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showed a focal staining profile, with several degrees of
intensity. The AHA staining profile also showed some
variation from MPAin regard to the proportion of pos-
itive tumour cells in prostatic carcinomas (Fig. 12).
ECA showed the same staining pattern as AHA, and
bound to the majority of tumour cells (Fig. 13). In
comparison to AHA and ECA, CTA gave an inconsis-
tent staining pattern with variable proportions of posi-
tive neoplastic cells (Fig. 14). 
SNAand MAA. SNAshowed very strong granular
staining patterns covering all parts of the neoplastic
epithelial cells, except the nucleoplasm, in the vast
majority of cases of prostatic carcinomas (Fig. 15). In
comparison, the MAAstaining profile was variable, in
respect of intensity, among the tumour cells. It differed
from case to case, yielding a patchy staining pattern in
some cases and a focal staining pattern in others (Fig.
16). It appeared that fewer than 60% of the tumour
cells bound to MAA in most of the cases of prostatic
carcinoma.
GNA and NPA. Both GNA and NPA showed the
same staining pattern, demonstrated by moderate to
strong, granular, cytoplasmic staining, mostly apical
and in the supra-nucleus, which did not change after β-
elimination, but slightly increased after dilute acid.
Pre-treatment by β β-elimination and dilute acid.
Pre-treatment by β-elimination revealed a dramatic
loss in both cellular and stromal staining of most
lectins, except a moderate increase in MAA-staining,
in some tumours, but a decrease in others, while SNA
staining remained constant or was increased (Table 3).
In contrast, pre-treatment with dilute acid gave a con-
siderable increase in both cellular and stromal staining
of all lectins except SNA-staining remained
unchanged (Table 3).
Discussion
In this study, the first group of markers AAA, UEA-1,
DBA, MAb Lea, MAb sLea and MAb sLex demonstrat-
ed the presence of several fucosylated glycans of type I
and type II chains in prostatic carcinomas. These find-
ings are consistent with the observations of previous
lectin studies [6-8], except for McMahon et al [9] who
found no staining with the lectins directed against fuco-
sylated structures (UEA-1 and LTA), and Loy et al [10],
McNeal & Alroy et al [11] and Drachenberg 
& Papadimitriou [12] who found no staining with DBA.
These exceptions can be explained by understanding the
possible biochemical pathway of the synthesis of 
The staining intensity of lectin reaction was graded as, ++++: very strong binding; +++: strong binding; ++: moderate binding; +: weak binding; -: nega-
tive staining.
Table 2. Lectin and monoclonal antibodies binding patterns of normal and cancerous prostatic tissuesUEA-1, AAAand DBAacceptors, which starts with the
fucosylation of the disaccharide precursor core (Galβ1-
3/4GlcNAc) by α1, 2-fucosyltransferase to become
Fucα1-2Galβ1-3/4GlcNAcβ1- (UEA-1 or AAA lig-
and). The next step is the addition of GalNAc residues
by a specific 2 deoxy, 2acetamidogalactosyltransferase
to produce GalNAcα1-3(Fucα1-2) Galβ1-
3/4GlcNAcβ1- (DBA ligand). 
In respect of Lewis antigens, the results of this
study showed low expression of Lea [13-15]. Howev-
er, a comprehensive search of the available literature
has found only one study investigating the expression
of sLea antigen. Zhang et al found that one prostatic
carcinoma out of five expressed sLea in more than
50% of the tumour cells [16], but they did not report
the level of expression in the other cases, therefore,
their findings are not inconsistent with the results of
this present study. Nevertheless, Jorgensen et al [17],
Martensson et al [18], Jorgensen et al [19] and Idikio
[20] found up-regulation of sLex expression, which is
also consistent with the observations of this present
study, and they associated this with increased potential
for tumour progression and poor prognosis.
The results of WFA, VVAand HPA, before and after
pre-treatment with dilute acid, confirmed the presence
of structures rich in N-acetylgalactosaminyl termini
(Table 4), and possibly their sialylated forms. These
findings are consistent with the results of McMahon et
al, who found increased expression of WFA and HPA
ligands and down regulation of VVA ligands [9].
While, Arenas et al found weak HPA staining [6],
which might be a result of using different disclosing
methods from McMahon et al and this current study.
WFA binds to GalNAcα1,6Galβ1- with an affinity
about fifty times greater than that it shows to
GalNAcα1,3Galβ1- on both type I and II chains. Mass
action versus affinity to WFA ligands, in this study,
seemed to be very commonly expressed in the trans-
formed prostatic epithelial cells in prostate tumours. In
comparison, VVA, which has a much higher affinity
for GalNAcα1,3Galβ1- than GalNAcα1,6Galβ1-,
showed a dramatic down-regulation in the expressions
of VVAligands. This argues that, WFAis largely bind-
ing to α1, 6 linked ligands. In addition, the increase in
WFA and VVA staining after pre-treatment with dilute
acid shows that the synthetic pathway for the carbohy-
drate sequence GalNAcα1,6Galβ1- was highly active
in prostatic carcinoma. Dilute acid pre-treatment
revealed the presence either of sialylated forms of the
WFA and VVA ligands, or that at least some of the
WFA and VVA ligands are hindered by other sialyl
glycans, or both. 
HPA specifically binds terminal 2deoxy, 2acetami-
dogalactosyl residues in sugar chains (for example, Tn
antigen and histo-blood group Adeterminant and DBA
ligands). Although HPA belongs to a protein family
unrelated to VVA and WFA, it can, to a lesser extent,
recognise the GalNAc residues of the WFA and VVA
ligands. This may well explain the differences in stain-
ing patterns between HPA and both WFA and VVA.
However, because of the diminished staining with
DBA and VVA, it is more likely that the strong stain-
ing of HPA is a result of increased synthesis of Tn
antigen and, perhaps, WFAligands. This was also con-
firmed by the observations after the dilute acid pre-
treatment, which showed also the presence of sTn anti-
gen and the sialylated type of GalNAcα1-6Galβ1-
3/4GlcNAcβ1-. These are consistent with the observa-
tions of Zhang et al, who used antibodies against Tn
and sTn antigens and found their expression in almost
all cases of prostatic carcinoma [16].
BSA-1B4 lectin showed the presence of Galα1,
GalαΑ1-3(Fucα1-2) Galβ1-4GlcNAc- and Galα1-
3Gal-, especially after pre-treatment with dilute acid
[11]. However, MPA and ECA staining confirmed, to
some extent, the presence of Galα1- and Galα1-
3Galβ1-4GlcNAcβ1- respectively.
In MPA, ECA, CTA and AHA group of lectins
mainly confirms the occurrence of several different
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↓ = Slight decrease in stain; ↓↓ = moderate decrease in stain; ↓↓↓ = sharp
decrease in stain; ↑ = slight increase in stain; ↑↑ = moderate increase in
stain; ↑↑↑ = sharp increase in stain; =: no change;  ↑/= = slight increase in
staining of some cases and unchanged in others; ↓/↑ = Slight decrease in
staining of some cases and slight increase in staining of others;  ↓↓/↑ =
moderate decrease in staining of some cases and slight increase in staining
of others
Table 3. Effects of pre-treatment by β elimination and dilute acid
pre-treatment (removing sialic acid).types of galactosylated glycans in carbohydrate
sequences expressed on transformed prostatic epitheli-
um. These observations are consistent with the find-
ings of Foster et al [21], and McMahon et al [9] for
ECA staining, Soderstrom [8], McNeal & Alroy et al
[11], Foster et al [21], McMahon et al [9], Drachen-
berg & Papadimitriou [12], Janssen et al [22] and Are-
nas et al [6] for AHAstaining. The data-analysis of this
present study suggests that there is increased synthesis
of the precursor of type II chain Gal 1-4GlcNAc in
long and multiply branched carbohydrate chains, fol-
lowed by increased galactosylation and 2-deoxy-2-
acetamidogalactosylation. There is also increased syn-
thesis of the structure Galβ1-3GalNAcα1- (core 3). 
The results of using MAA and SNA in the present
study clearly demonstrate the presence of hypersialy-
lation, which is a common observation in transformed
cells in many kinds of tumours including prostatic car-
cinoma [6,23-26]. However, McMahon et al [9] found
increased expression of SNA ligands, but not MAA
ligands. This finding, in regard to MAA, does not con-
tradict the observations of this present study, as it was
found that there was a group of cases of prostatic car-
cinoma (4 out of 27) which did not bind to MAA but
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©Polish Histochemical et Cytochemical Society
Folia Histochem Cytobiol. 2010:48(4): 643 (637-645) 
Doi: 10.2478/v10042-010-0089-9
Table 4. The carbohydrate structures recognised by the combination of markers of the present study.
Fuc: fucose; Gal: galactose; GlcNAc: 2 deoxy, 2 acetamidoglucosyl residue; GalNAc: 2 deoxy, 2 acetamidogalactosyl residue; NeuAc: sialic acid; Man:
mannose; MAb Lea: monoclonal antibody against Lewisa antigen; MAb sLea: monoclonal antibody against sialyl Lewisa antigen; MAb sLex: monoclonal
antibody against sialyl Lewisx antigen.bound to either sLex or sLea or to both of them. This
means that expression of NeuAcα2-3- was present, but
was not recognised by MAA, most probably because
of steric constraints caused by the fucosyl residues of
sLex and sLea structures. Nevertheless, the findings of
this study allow for the confident prediction of the pos-
sible presence of certain sialylated structures listed in
Table 4. The results, in the present study, indicated that
the main biosynthetic pathways of sialylation are
through α2-3 and α2-6 linkages, synthesised by α3-
sialyltransferase (ST3Gal) and α6-sialyltransferase
(ST6Gal) families respectively.
Two lectins, GNA and NPA, showed the presence
of α-D-mannose residues in prostatic carcinoma, espe-
cially in Man 1-3Man and Manα1-6Man linkages
respectively. This is consistent with the findings of
Arenas et al [6] who also found strong staining by
GNA and NPA in transformed prostatic cells. The best
explanation is that α-D-Man residues were added in
both linkages to immature N-glycans sequences in
early stages of their biosynthesis in endoplasmic retic-
ulum or the Golgi apparatus. These N-glycans then
were subjected to further modifications, by the actions
of, first, mannosidases and, then, glycosyltransferases,
which added different glycosyl residues such as Gal,
GalNAc, GlcNAc, Fuc and sialic acids. This explana-
tion is supported by the location of staining in the api-
cal cytoplasm and in the supra-nuclear region (Fig.
17), and also the results of staining by other lectins
used in this present study, especially after β-elimina-
tion which showed that the changes of glycosylation
observed were present on both O- and N-glycans. An
alternative explanation is that the accumulation of
lectin-binding material in the cytoplasm may be
indicative of acceleration in synthesis, or a breakdown
in transport mechanisms, so that the carbohydrate
structures are being produced faster than they could be
transferred to the cell surface.
Lectin binding to prostatic carcinoma following β-
elimination, showed that most of the carbohydrate
structures demonstrated by the lectins used in this
study are carried on O-glycans, as there was a dramat-
ic decrease in staining intensity after β-elimination,
except for WFA, BSA-1B4, GNA, NPA, MAA and
SNA, which showed increased or unchanged staining
in some cases (Table 3). A likely explanation for these
results is that the steric hindrance caused by O-glycans
has been removed, thus much more N-glycans have
been recognised by lectins. Alternatively, the ligands
of these lectins, especially for GNA and NPA, are car-
ried only on N-glycans. However, the same changes of
glycosylation observed on O-glycans also occurred on
N-glycans since some staining was retained following
β-elimination. All these changes occurred on the ter-
minal parts of the O- and N-glycans because most of
the lectins, if not all, bind to terminal residues.
A great number of the carbohydrate structures
demonstrated in this study were sialylated either
through α2-3 or β2-6 linkages, since staining by most
lectins was considerably increased following dilute
acid pre-treatment, except for SNA and MPA and in
some cases WFA, MAA, GNA and NPA, which
showed slightly increased or unchanged staining. It is,
thus, possible that staining level of some lectins may
remain the same as a result of 'balanced losses, i.e.,
losing long chain glycans but revealing hidden short
chain glycans. So, there is no change in the overall
level of staining, but there is a change in the distribu-
tion pattern of binding among the cell populations in
the tissue sections. Another explanation is that the
presence sialyl residues do not restrict the recognition
of glycans by lectins.
Conclusion 
The findings of this study showed that the glycan
phenotype of transformed prostatic cells is different
from their normal counterparts. The malignant pro-
static cells had a distinct glycophenotype, which was
demonstrated by an increase of fucosylation, galacto-
sylation, 2 deoxy, 2 acetamide galactosylation or
masking of carbohydrate residues. Lectin staining, in
this present study, enabled both the accurate identifi-
cation of cells displaying the marker in question and,
in addition, allowed one to determine whether the
particular marker is intracellular or membranous.
Much of the variation in binding appeared to be relat-
ed to cellular differentiation and maturation. Some
lectins showed, to some extent, focal and patchy
staining, in some if not all cases. This finding sug-
gests that transformed prostatic cells, which appeared
to be of equivalent differentiation and maturation,
and appeared to be morphologically identical actual-
ly displayed different cell surface glycoconjugates.
This might reflect cells with differing functions and
capabilities. This is especially important when study-
ing heterogeneous tissues such as epithelial lesions,
where expression may vary between the various tis-
sue components.
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